News

Fine-chemical producers and contract API manufacturers expand capacity and expand service offerings.

Excipients market will be shaped by greater supply-chain concerns, quality-by-design programs,and overall drug-safety issues.

Overall growth in the market for pharmaceutical contract research and manufacturing is strong although growth in established markets erodes at the expense of emerging markets.

PharmTech spoke with Dow about innovations in polymers to address poor solubility.

Beckman Coulter Life Sciences combines its particle characterization business with the Hach Company particle counting business.

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

Pliva?s new Oral Solid Forms Facility will increase Pliva's production capacities for tablets and capsules.

Pharmaceutical Technology speaks with PolyOne, a provider of specialized polymer materials, services and solutions about the company?s product, Versaflex HC, for infusion therapy stoppers and septums.

Brian Scanlan, CEO and president of Cambridge Major Laboratories, discusses the rationale behind the company's merger with AAIPharma Services.

Winners for the 2013 CPhI Pharma Awards, which recognize pharmaceutical innovation, will be awarded on later today, Tuesday Oct. 22.

The Aenova Group will merge with Haupt Pharma, a company specializing in contract development and manufacturing.

FDA is seeking a permanent injunction against a dietary supplement manufacturer following the company?s repeated distribution of unapproved drugs and adulterated dietary supplements.

FDA has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases.

Capsule design was developed for patients who have difficulty swallowing.

Novozymes Biopharma will collaborate with Almac to provide a combined service for drug development applications.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

Interview of Detlev Haack, head of R&D, Hermes Pharma on the characteristics, benefits and manufacturing Methods of effervescent tablets

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedPharm opens a new topical and transdermal formulation-development services facility in Guildford, United Kingdom.

The CDMOs DPT Laboratories and Confab will integrate under the leadership of Paul Johnson, group president and COO.

Penn Pharma partners with GEA Pharma to open a new facility for the development and manufacture of oncology drugs.

The success of Adcetris and Kadcyla is paving the way for more antibody drug conjugates to enter the market, especially in the treatment of solid tumors.

ISPE has announced the results of its 2013-2014 International Board of Directors election.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

The FDA grants Cornerstone Pharmaceuticals orphan drug designation for CPI-613 for the treatment of myelodysplastic syndrome.

Roche's plans for a major biologics manufacturing expansion is the latest investment by Big Pharma

Kansas State University to build Bulk Solids Innovation Center in Salina, Kansas.

AstraZeneca and SAFC are the latest companies to expand positions in antibody drug conjugates (ADCs).

CPhI Worldwide starts off with a conference program on Monday 21 October.